EPIRUS Biopharm Inc (fka EPRSQ)

[The Night Stalker]

going to sub penny then a 1000% bounce

[Lone Wolf]

Agree...surprised at the steady volume...would have thought it would have progressively dropped off.

[The Night Stalker]

sleeper

[Lone Wolf]

Holy chit...what's making you move?!? I want to see some volume now...before I start slapping again.

[Lone Wolf]

Funny watching the buying here in this 'wind down play' as everyone's now on the hunt for the next ST*M.

[Value_Investor]

EPRSQ hit another New low 0.041! 0.00x should be hit within a few weeks... It is a CH7 Q stock now without any investment value! So it should follow its CH7 Q peers to hit the $69K MV or at the New low price $0.0026...

[Lone Wolf]

Hmmmm....someone's buying today.

[The Night Stalker]

http://www.stockscores.com/chart.asp?TickerSymbol=eprsq&TimeRange=30&Interval=120&Volume=1&ChartType=OHLC&Stockscores=1&ChartWidth=830&ChartHeight=500&LogScale=None&Band=None&avgType1=SMA&movAvg1=8&avgType2=SMA&movAvg2=34&Indicator1=RSI&Indicator2=PPO&Indicator3=AccDist&Indicator4=MFI&endDate=&CompareWith=&entryPrice=&stopLossPrice=

[Lone Wolf]

Thinking today I'll buy a lottery ticket here. A new week is dawning. Let's see what that 'dice roll' produces.

[Lone Wolf]

Lots of interest here in the mid-5's. My money says someone will run this within the next week or two.

[Lone Wolf]

I'm very intrigued seeing all the bidding here. Time for a new run?

[Value_Investor]

Cool! You can easily buy them back at 0.01 very soon...

[k00lrav]

I cut my losses and made a few back on that dead cat bounce.

[Value_Investor]

Another new 52-week low $0.07 was hit a while ago! Sell EPRSQ ASAP before the symbol is changed to EPRSQ...

[Renee]

EPRS changed to EPRSQ, bankruptcy. Delisted from the Nasdaq to the OTC:

http://otce.finra.org/DLAdditions

[@MomoPicks]

I smell a few Bulls coming. .18

[ArmenianKing]

Agree not touching this sticking with my BGI

[retireat40]

Yep...amazing that people buy this crap.

[ClayTrader]

* * $EPRS Video Chart 07-27-16 * *

Link to Video - click here to watch the technical chart video

[pberger]

You just missed 200%, too bad.

[Attote]

tem 1.01. Entry into a Material Definitive Agreement and Item 1.02. Termination of a Material Definitive Agreement.

On July 15, 2016, EPIRUS Biopharmaceuticals, Inc. (the “Company”) (through its Swiss subsidiary) entered into a Settlement Satisfaction Amendment (the “Livzon Satisfaction Amendment”) with Livzon Mabpharm Inc. (“Livzon”) relating to the conveyance of certain of the Company’s rights related to its BOW070 (tocilizumab) biosimilar product, which was being developed with Livzon under the BOW070 Collaboration Compound Agreement between the Company and Livzon, dated as of September 24, 2015 and the Exclusive License and Collaboration Agreement between the Company and Livzon dated as of September 24, 2014 (collectively, the “Livzon Agreements”). Pursuant to the terms of the Livzon Satisfaction Amendment, the Company sublicensed to Livzon exclusive rights in certain territories with respect to the Company’s BOW070 technology. The Company also assigned to Livzon its rights, title and interest to all BOW070 cell-line clones and development reports and related materials. In consideration for these rights, the parties have agreed to terminate the Livzon Agreements, and Livzon has released the Company from the obligation to make any further payments thereunder.

On July 18, 2016, the Company (through its Swiss subsidiary) entered into a Settlement Satisfaction Agreement (the “Reliance Satisfaction Agreement”) with Reliance Life Sciences Pvt. Ltd. (“Reliance”) relating to the Company’s conveyance to Reliance of its rights, title, interest and obligations in each of the following agreements: (i) the BOW015 License Agreement between the Company and Sun Pharmaceuticals Ltd. (“Sun Pharma”) dated as of January 3, 2014 (as amended, the “Sun-Epirus License Agreement”), and the Supply Agreement between the Company and Sun Pharma, dated September 5, 2014; and (ii) the GPEx® Cell Line Sale Agreement between the Company (as assignee from Moksha8 Pharmaceuticals, Inc.) and Catalent Pharma Solutions, LLC, dated January 1, 2009, for all rights and obligations to BOW015 (infliximab) cell banks created and held by Catalent to express the Infimab® product sold by Sun Pharma. Additionally, pursuant to the terms of the Reliance Satisfaction Agreement, the Company will transfer to Reliance certain clinical trial data for use outside of India for BOW015 infliximab and will transfer the BOW015 IND license relating to certain infliximab proteins, which was filed with the Indian regulatory authorities under the name of Reliance on behalf of the Company, together with BOW015 regulatory filings made in Indonesia and Thailand in the name of Zuellig Pharma Limited. In consideration for these rights, Reliance has released the Company from the obligation to make any further payments under that certain Settlement Agreement dated as of April 22, 2015, as amended.

The Company has received a termination notice from BTIG, LLC (“BTIG”), effective July 13, 2016, relating to the At-the-Market Sales Agreement with BTIG, dated as of February 29, 2016, pursuant to which the Company had the ability to sell at its option from time to time up to an aggregate of $30 million in shares of the Company’s common stock, $0.001 par value per share, through BTIG, as sales agent.

Item 1.03. Bankruptcy or Receivership.

On July 25, 2016, the Company filed a voluntary petition for relief under the provisions of Chapter 7 of Title 11 of the United States Code, 11 U.S.C. §§ 101 et seq. (the “Code”) in the United States Bankruptcy Court for the District of Massachusetts (the “Bankruptcy Court”). As a result of this filing, a Chapter 7 trustee will be appointed by the Bankruptcy Court and will assume control of the Company. The assets of the Company will be liquidated and claims paid in accordance with the Code.

1


Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.

In connection with the bankruptcy filing, the Chapter 7 trustee will assume control over the assets and liabilities of the Company. Accordingly, on July 25, 2016, all of the Company’s directors have resigned from their positions as directors of the Company. As of such date, the directors of the Company were Mark H.N. Corrigan, M.D., J. Kevin Buchi, Daotian Fu, Ph.D., Geoffrey Duyk, M.D., Ph.D., William Hunter, M.D., Julie McHugh and Scott Rocklage, Ph.D. who also concurrently resigned from his position as the Company’s Chief Executive Officer.

Item 8.01. Other Events.

In connection with the bankruptcy filing, the Company’s Board of Directors terminated the employment of the Company’s remaining employees, effective as of July 25, 2016.

[Attote]

Artículo 1.01. La entrada en un acuerdo definitivo Material y artículo 1.02. La terminación de un acuerdo definitivo de materiales.

El 15 de julio, 2016, EPIRO biofarmacéuticos, Inc. (la "Compañía") (a través de su filial suiza) entró en una satisfacción de Solución de enmienda (la "satisfacción Livzon Enmienda") con Livzon Mabpharm Inc. ( "Livzon") en relación con el transporte de algunos de los derechos de la Compañía relacionados con su BOW070 (tocilizumab) producto biosimilar, que se está desarrollando con Livzon bajo el Acuerdo Compuesto BOW070 la colaboración entre la Sociedad y Livzon, de fecha de 24 de septiembre, 2015, y la Licencia y Colaboración acuerdo exclusivo entre la Sociedad y Livzon de fecha 24 de septiembre de 2014 (conjuntamente, los "Acuerdos Livzon"). De conformidad con los términos de la satisfacción Livzon modificación, la Sociedad otorgar una segunda licencia para Livzon derechos exclusivos en determinados territorios con respecto a la tecnología BOW070 de la Compañía. La compañía también asigna a Livzon sus derechos, títulos e interés para todos los clones de la línea celular BOW070 e informes de desarrollo y materiales relacionados. En consideración a estos derechos, las partes han acordado poner fin a los Acuerdos Livzon, y Livzon ha lanzado la compañía de la obligación de efectuar nuevos pagos en virtud del mismo.

El 18 de julio de 2016, la Sociedad (a través de su filial suiza) entró en un Acuerdo de Solución de satisfacción (el "Acuerdo de satisfacción Reliance") con Reliance Life Sciences Pvt. Ltd. ( "dependencia") en relación con el transporte de la Compañía de dependencia de sus derechos, títulos, intereses y obligaciones en cada uno de los siguientes acuerdos: (i) el contrato de licencia BOW015 entre la Compañía y Sun Pharmaceuticals Ltd. ( "Sun Pharma" ) de fecha 3 de enero de 2014 (en su versión modificada, el "Acuerdo de licencia de Sun-Epiro"), y el acuerdo de suministro entre la Compañía y Sun Pharma, de 5 de septiembre, 2014; y (ii) el acuerdo de venta de la línea celular GPEx® entre la Sociedad (como cesionario de Moksha8 Pharmaceuticals, Inc.) y soluciones de Catalent Pharma, LLC, de fecha 1 de enero de 2009 para todos los derechos y obligaciones de BOW015 (infliximab) creado bancos de células y en poder de Catalent para expresar el producto Infimab® vendido por Sun Pharma. Además, de conformidad con los términos del Acuerdo de satisfacción Reliance, la Compañía transferirá a la dependencia de ciertos datos de los ensayos clínicos para su uso fuera de la India por BOW015 infliximab y transferirá la licencia BOW015 IND relativa a ciertas proteínas infliximab, que fue presentada ante el regulador de la India autoridades bajo el nombre de Reliance en nombre de la empresa, junto con BOW015 presentaciones regulatorias realizadas en Indonesia y Tailandia en nombre de Zuellig Pharma Limited. En consideración a estos derechos, Reliance ha lanzado la compañía de la obligación de efectuar nuevos pagos en virtud de que ciertos Acuerdo de Resolución de fecha de 22 de abril de 2015, en su versión modificada.

La Compañía ha recibido un aviso de terminación de BTIG, LLC ( "BTIG"), a partir del 13 de julio de, 2016, relativo al Acuerdo de Ventas at-the-mercado con BTIG, de fecha 29 de febrero de 2016, conforme a los cuales la Compañía tenía la posibilidad de vender a su opción de vez en cuando, hasta un total de $ 30 millones en acciones comunes de la Compañía, $ 0.001 de valor nominal por acción, a través de BTIG, como agente de ventas.

Artículo 1.03. Quiebra o suspensión de pagos.

El 25 de julio de 2016, la Compañía presentó una petición voluntaria para el alivio bajo las disposiciones del Capítulo 7 del Título 11 del Código de los Estados Unidos, 11 USC §§ 101 y ss. (El "Código") en el Tribunal de Quiebras de los Estados Unidos para el Distrito de Massachusetts (el "Tribunal de Quiebras"). Como resultado de esta presentación, un administrador del Capítulo 7 será designado por la Corte de Quiebras y asumirá el control de la Compañía. Los activos de la Sociedad serán liquidados y las reclamaciones pagadas de conformidad con el Código.

1


Artículo 5.02. Salida de Administración o ciertos oficiales; Elección de Directores; Nombramiento de ciertos oficiales; Acuerdo de compensación de ciertos oficiales.

En relación con la declaración de quiebra, el administrador del Capítulo 7 asumirá el control sobre los activos y pasivos de la Compañía. En consecuencia, el 25 de julio de 2016, todos los directores de la compañía han renunciado a sus cargos como directores de la Compañía. A partir de dicha fecha, los directores de la Compañía fueron Mark HN Corrigan, MD, Kevin J. Büchi, Daotian Fu, Ph.D., Geoffrey Duyk, MD, Ph.D., William Hunter, MD, Julie McHugh y Scott Rocklage , Ph.D. quien también renunció al mismo tiempo de su cargo como CEO de la compañía.

Tema 8.01. Otros eventos.

En relación con la declaración de quiebra, el Consejo de Administración de la Sociedad concluya la relación laboral de los empleados restantes de la Compañía, a partir del 25 de julio de 2016.

[TrendTrade2016]

This ticker working well into the EOD. No trend here yet so be careful. scalped out but watching close

glta
trendtrade2016

[declaes]

On July 25, 2016, the Company filed a voluntary petition for relief under the provisions of Chapter 7 of Title 11 of the United States Code, 11 U.S.C. §§ 101 et seq. (the “Code”) in the United States Bankruptcy Court for the District of Massachusetts (the “Bankruptcy Court”). As a result of this filing, a Chapter 7 trustee will be appointed by the Bankruptcy Court and will assume control of the Company. The assets of the Company will be liquidated and claims paid in accordance with the Code.

Chapter 7... This will go to zero... Be careful

[The_BORG]

i find overall ZERO information !
CHAPTER 7 an liquitation is the old and actually fact
this run today, out of nothing, was a 100% extrem clear short-squeeze !
the shorts burnt off today completly ...this was all

back to under $0,1 at status Q

and YES .... Shi..t ... i missed this run completly

[OTCWealth101]

Chapter 7 people shares will be worthless, this is just a dead bounce so that tutes get out at your cost

[ClearlyStocks]

.265 for me. Thank you. All out

[SidewaysTrader]

It looks to me like a frontloading bull raid and I think the bull left the stadium.

[ClearlyStocks]

In .23 for starter

[tripil7z]

$EPRS in at .213 on that pullback

[The_BORG]

OS 26,2 Mio
in 2hr 15 Mio dealing
?????????????????????

[UP Trend]

I sleep in and miss my buy at .09 then sell too early, oh well profit is profit

[ClearlyStocks]

.29 careful now.

[wochsac]

I'll Short this POS

[ClearlyStocks]

.22 went bye bye

[ClearlyStocks]

What just happened?

[UP Trend]

Sold for a quick flip. Probably bit too early though

[wochsac]

Bankrupt and up 100% .. LOL

[UP Trend]

Shoot, missed this easy setup.

[TrendTrade2016]

This ticker moving on a scalp trade. Trade with caution.

GLTA
Trentrade2106

[k00lrav]

whats with the slapping towards the end? due to the recent news I would assume it would have been straight dumping.

[Value_Investor]

Another new 52-week low $0.09 was hit a while ago! Sell EPRS ASAP before the symbol is changed to EPRSQ...

[k00lrav]

Bit strange watching the L2 with all the buys happening as well.

[Value_Investor]

New low $0.091 was created today as I predicted yesterday! More new lows will kick in very soon... The ending "Q" will be added as well!

[Value_Investor]

Yes. New low $0.1 was just created today! $0.0x very soon...

[The_BORG]

i think the $0,0x it will come today because of CH7 the paper's are absolute worthless...that is 100%
and so the people get $0,10+x pps... better than $0,0x or $0,00x in the next days

[The_BORG]

good question

*gambler
*short-Addresses cover their open positions before is over
*unknowing people
*unbeliever
*and a lot of other undefined people

[ArmenianKing]

Why would anyone buy shares if their going under?

[Liquid1974]

That's awful.. Chapter 7 is closing doors...

[Value_Investor]

The CH7 pos scam just hit $0.104 today! $0.0x will be hit tomorrow...